| Outcome Measures: |
Primary: Number of treatment-emergent adverse events (AEs), Number of events, Part 1 and 2: From trial product administration at Visit 2, day 1 until completion of post treatment end-of-trial visit at Visit 6, day 10|Number of treatment-emergent adverse events (AEs), Number of events, Part 3: From trial product administration at Visit 2, day 1 until completion of post treatment end-of-trial visit at Visit 4 (up to 33 days after Visit 2, day 1) | Secondary: Number of treatment-emergent hypoglycaemic episodes, Number of episodes, Part 1 and 2 From trial product administration at Visit 2, day 1 until completion of post treatment end-of-trial visit at Visit 6, day 10|Number of treatment-emergent hypoglycaemic episodes, Number of episodes, Part 3: From trial product administration at Visit 2, day 1 until completion of post treatment end-of-trial visit at Visit 4 (up to 33 days after Visit 2, day 1)|Area under the serum NNC0363-0845 concentration-time curve from 0 to infinity after a single dose, pmol\*h/L, Part 1 and 2 From 0 hours until last measurement time after trial product administration (Visit 2, day 1)|Area under the serum NNC0363-0845 concentration-time curve from 0 to infinity after a single dose, pmol\*h/L, Part 3: From 0 hours until last measurement time after trial product administration (Visit 2, day 1 and Visit 3, day 1)|Maximum observed serum NNC0363-0845 concentration after a single dose, pmol/L, Part 1 and 2 From 0 hours until last measurement time after trial product administration (Visit 2, day 1)|Maximum observed serum NNC0363-0845 concentration after a single dose, pmol/L, Part 3: From 0 hours until last measurement time after trial product administration (Visit 2, day 1 and Visit 3, day 1)
|
